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onstrating their superiority to BMS in reducing major adverse 
cardiac events (MACE) in native coronary artery disease (1-4). 
However, the use of DES in saphenous vein graft (SVG) and 
the long-term MACE outcome has not been yet demonstrat-
ed in larger studies over longer follow-up periods. Occlusion 
rates of SVG over 10 years are 40%, and of those grafts that 
do not occlude 43% will have significant stenosis (5). Despite 
the fact that up to 10% of PCIs are done in SVG (6), these le-
sions have been either poorly represented or excluded from 
pivotal clinical trials (1, 2). However, the degeneration of SVG 
appears to be different compared with the progression of 
coronary artery atherosclerosis in native vessels (7, 8). In na-
tive vessels the cause of restenosis is almost exclusively due 
to neointima proliferation (9) while in SVGs variable degrees 
of contribution have been reported for thrombus forma-
tion, cellular hyperplasia and progression of atherosclerotic 
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ABsTRAcT
Background: Research trials have shown improved short-term outcome with drug-eluting stents (DES) over bare 
metal stents (BMS) in saphenous vein graft (SVG) percutaneous coronary intervention (PCI), primarily by reducing 
target vessel revascularization (TVR) for in-stent restenosis. We compared the outcomes in patients undergoing 
SVG stent implantation treated with DES or BMS. In exploratory analyses we investigated the influence of stent 
generation and diameter.
Methods: Data were obtained from a prospective database of 657 patients who underwent PCI for SVG lesions 
between 2003 and 2011. A total of 344 patients had PCI with BMS and 313 with DES. Propensity scores were de-
veloped based on 15 observed baseline covariates in a logistic regression model with stent type as the dependent 
variable. The nearest-neighbour-matching algorithm with Greedy 5-1 Digit Matching was used to produce two pa-
tient cohorts of 313 patients each. We assessed major adverse cardiac events (MACE) out to a median of 3.3 years 
(interquartile range: 2.1-4.1). MACE was defined as all-cause mortality, myocardial infarction (MI), TVR and stroke.
Results: There was a significant difference in MACE between the two groups in favour of DES (17.9% DES vs. 
31.2% BMS group; p = 0.0017) over the 5-year follow-up period. MACE was driven by increased TVR in the BMS 
group. There was no difference in death, MI or stroke. Adjusted Cox analysis confirmed a decreased risk of MACE 
for DES compared with BMS 0.75 (95% confidence interval (CI) 0.52-0.94), with no difference in the hazard of all-
cause mortality (hazard ratio: 1.08; 95% CI: 0.77-1.68). However, when looking at stent diameters greater than 
4 mm, no difference was seen in MACE rates between BMS and DES.
Conclusions: Overall in our cohort of patients who had PCI for SVG disease, DES use resulted in lower MACE rates 
compared with BMS over a 5-year follow-up period; however, for stent diameters over 4 mm no difference in 
MACE rates was seen.
Keywords: Bare metal stent, Drug-eluting stent, Percutaneous intervention, Stroke, Target vessel revascularisa-
tion, Venous graft
Introduction
Drug-eluting stents (DES) are now widely used in prefer-
ence to bare metal stents (BMS) for elective and emergency 
percutaneous coronary intervention (PCI), with studies dem-
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process (10). Due to the difference in pathophysiology of vein 
graft stenosis, the outcome of DES in native coronary artery 
disease cannot be directly translated to this different clinical 
setting (11). The question arises as to whether the long-term 
advantages of DES over BMS in reducing restenosis are offset 
by increased MACE driven by late stent thrombosis, whether 
different DES types have different outcomes and whether the 
size of the stent affects the outcome. To address this we stud-
ied a large cohort of consecutive patients undergoing SVG 
PCI with the aim of comparing long-term outcomes for those 
treated with DES and BMS. We also investigated the influence 
of stent diameter on MACE during the follow-up period.
Methods
This was a retrospective observational cohort study in a 
high-volume interventional centre of patients with vein graft 
disease treated with either DES or BMS. The study period was 
from January 2003 to July 2011. During this period, 15,569 
consecutive patients underwent PCI, of whom 13,422 (86%) 
with complete database records and National Health Service 
numbers were available for analysis. A total of 657 patients 
with stable angina, unstable angina or non-ST elevation acute 
coronary syndrome (NSTEACS) underwent PCI for the treat-
ment of SVG stenosis. Patients undergoing primary PCI were 
excluded as BMSs were routinely used for the majority of the 
study period as per local guidelines.
Data were prospectively entered into a clinical PCI data-
base at the time of the procedure. Data collected included 
patient characteristics (age, prior myocardial infarction (MI), 
PCI and coronary artery bypass grafting (CABG), hyperten-
sion, diabetes mellitus, hypercholesterolaemia, peripheral 
vascular disease (PVD), New York Heart Association class, 
smoking status, chronic renal impairment (chronic renal fail-
ure (CRF): creatinine >200 µmol/l or on renal replacement 
therapy), left ventricular (LV) function and cardiogenic shock) 
and procedure-related data (indications for PCI, target vessel, 
number of diseased vessels, use of intravascular ultrasound 
(IVUS)/pressure wire, use of DES and glycoprotein (GP) IIb/
IIIa inhibitor).
Interventional strategy was at the discretion of the opera-
tor, including the use of direct stenting, pre/post-dilatation, 
IVUS, adjunctive antiplatelet therapy and use of ablative de-
vices. Angiographic success was defined as residual stenosis 
<30% with Thrombolysis In Myocardial Infarction (TIMI) flow 
grade 3. All patients received aspirin 300 mg and either clopi-
dogrel 300 mg or 600 mg prior to the procedure. All patients 
were prescribed 75 mg aspirin and 75 mg clopidogrel main-
tenance therapy. Clopidogrel maintenance therapy was rec-
ommended for 1 month in the BMS group, 12 months in the 
DES group and 12 months for patients treated for NSTEACS. 
Unfractionated heparin was given during the procedure at a 
loading dose of 70 u/kg and the activated clotting time was 
maintained >250 sec. Glycoprotein IIb/IIIa inhibitors were 
used at the operator’s discretion and according to local guide-
lines.
Procedural complications and MACE were recorded pro-
spectively. MACE was defined as death, MI (new pathologic 
Q waves in the distribution of the treated coronary artery 
with an increase of creatine kinase MB to ≥2 times the 
reference value or significant rise in Troponin T values) and 
target vessel revascularization (TVR). These MACE rates 
were adjudicated by three independent physicians who 
were not involved in the procedure and were unaware of 
the patient’s stent type. Procedural complications recorded 
included MI, emergency CABG, arterial complications, aor-
tic/coronary dissection, side branch occlusion and arrhyth-
mia. Procedural complications were recorded at the time of 
the procedure and in-hospital complications were entered 
into the database at the time of discharge. Stent throm-
boses were defined according to the Academic Research 
Consortium (ARC) definition as angiographic or pathologic 
confirmation of partial or total thrombotic occlusion within 
the peri-stent region plus at least one of acute ischaemic 
symptoms, ischaemic electrocardiogram changes or ele-
vated cardiac biomarkers (12). Repeat PCI rates due to TVR 
were identified from the PCI database. All-cause mortal-
ity data were recorded as of 10 August 2011 and obtained 
via the British Cardiovascular Intervention Society national 
database, part of the National Institute of Cardiovascular 
Outcomes Research. This national database is periodically 
linked to the UK Office of National Statistics and provides 
live/death status of treated patients. Only patients who had 
complete database records and National Health Service 
unique numbers (allowing live/death status to be assessed) 
were included in the analysis. A retrospective data quality 
audit of 100 randomly selected medical records established 
that 94.8% of data fields, including complications, were en-
tered correctly into the database.
Ethics
Data were collected as part of a national cardiac audit and 
all patient-identifiable fields were removed prior to analy-
sis. The local ethics committee advised that formal ethical 
approval was not required.
Statistical analysis
Baseline patient, procedural and post-procedural charac-
teristics were compared between the two groups. Categorical 
data are summarized using absolute values (percentage). Nor-
mally distributed, continuous data are presented as mean ± 
standard deviation or, where skewed, as median (inter-quartile 
range). Normally distributed continuous variables were com-
pared using Student t-tests, and the Mann–Whitney U test 
was used to compare non-normally distributed continuous 
variables. Categorical data were compared using the Pearson 
chi-squared test.
Propensity matching
Baseline comorbidity was unbalanced between the DES 
and BMS groups. A non-parsimonious logistic regression mod-
el with stent type as the dependent variable (c-statistic, 0.785) 
was constructed to adjust for the confounding of baseline co-
morbidity and surgical complexity. Covariates in the model in-
cluded age, sex, previous MI, hypertension, previous stroke, 
PVD, LV ejection fraction, diabetes mellitus, CRF, acute coro-
nary syndrome (ACS) presentation, cardiogenic shock, stent 
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length and GP IIb/IIIa use. To balance comorbidity between 
the study groups, a greedy matching SPSS macro was used to 
match the 313 patients who underwent DES insertion with the 
344 patients from the BMS group with similar comorbidity. 
This created a “propensity-matched BMS” population.
Midterm survival was described using the Kaplan–Meier 
method, and comparisons were made using the log-rank sta-
tistic. Estimations of risk were calculated using Cox regression 
analysis. Potential independent predictors of outcome were 
identified by univariate Cox regression analyses, and all sig-
nificant univariate predictors (p<0.05) were then entered into 
the multivariate Cox regression model.
Influence of stent diameter and DES type on outcome
Subgroup analysis was performed based on the diameter 
of stent inserted, with patients split into above and below 
4 mm with further subgroup analysis based on the type of 
DES used.
Results
A total of 657 patients underwent PCI for SVG lesions, 
344 patients who underwent PCI with BMS and 313 treated 
with DES. The DES used was broken down into Taxus 128 (pa-
clitaxel), Cypher (sirolimus) 70, Resolute 20 (zotarolimus), 
Endeavor 122 (zotarolimus), Promus (everolimus) 37.
Patient and procedural characteristics (Tab. I)
Full unmatched study population
Baseline characteristics for both groups were similar 
apart from there being more patients with diabetes in the 
DES group (31.6% vs. 21.0%, p = 0.007) and more patients 
with ACS in the BMS group (31.4% vs. 22.0%, p = 0.02). An-
giographic success rates were similar for both groups (93.8% 
vs. 92.8%, p = 0.78). More stents per lesion were used in the 
DES group (1.5 ± 0.7 vs. 1.3 ± 0.6, p<0.0001), with a longer 
average length (22.0 ± 5.4 vs. 18.8 ± 3.9, p<0.0001). Average 
stent width was higher in the BMS group (3.7 ± 0.5 vs. 3.2 ± 
0.4, p<0.001).
Propensity matched population
After propensity matching, all baseline patient and proce-
dural characteristics were balanced between the two groups.
Outcomes after propensity matching (Figs. 1 and 2)
MACE after 5 years were less frequent with DES compared 
with BMS (17.9%, 95% confidence interval (CI) 9.3-14.2% vs. 
31.2%, 95% CI 16.9-25.1%, p = 0.017), driven largely by de-
creased TVR in the DES group (9.9%, 95% CI 6.0-11.5% vs. 
18.8%, 95% CI 13.0-22.3%, p = 0.018). Rates of target lesion 
revascularization were also significantly lower in the DES 
group (8.3%, 95% CI 5.2-10.1% vs. 17.2%, 95% CI 10.8-19.4%, 
p = 0.020). There was no difference in death, MI or stroke 
between the stent types (Fig. 2). Rates of definite/confirmed 
stent thrombosis were comparable for BMS and DES (3.2%, 
95% CI: 1.7-4.6% vs. 3.3%, 95% CI 1.4-4.4%, p = 0.6). There 
was no difference in the timing of stent thrombosis between 
the two groups with similar rates of late (1.6% vs. 1.3%) and 
very late thrombosis (1.6% vs. 1.5%). Procedural characteris-
tics according to stent type are illustrated in Table II.
Cox analysis (Fig. 3)
Adjusted Cox analysis confirmed a decreased risk of MACE 
for DES compared with BMS 0.75 (95% CI 0.52-0.94) with no 
TABLe I - Baseline patient characteristics according to stent type
Des 
n = 313
BMS 
n = 344
Significance
Age (mean) 66.8 ± 10 68.6 ± 7.4 0.13
Gender (female) (%) 45 (13.9) 47 (14.1) 0.20
Diabetes (%) 102 (31.6) 70 (21.0) 0.007
Hypertension (%) 176 (54.5) 182 (54.5) 0.98
Current smoker (%) 43 (13.3) 47 (14.1) 0.82
Hypercholesterolaemia  
(%)
143 (44.3) 137 (41.0) 0.34
Previous MI (%) 151 (46.7) 147 (44) 0.54
PVD (%) 4 (1.2) 6(1.8) 0.05
ACS Presentation 71 (22.0) 105 (31.4) 0.02
LVEF 50.44 ± 0.17 48.73 ± 0.19 0.52
Chronic renal failure 8 (2.5) 7 (2.1) 0.65
p<0.05.
ACS = acute coronary syndrome; BMS = bare metal stent; DES = drug-eluting 
stent; LVEF = left ventricular ejection fraction; MI = myocardial infarction; 
PVD = peripheral vascular disease.
Fig. 1 - Kaplan–Meier curve showing cumulative probability of 
MACE after PCI according to stent group. BMS = bare metal stent; 
DES = drug-eluting stent; MACE = major adverse cardiac events; 
PCI = percutaneous coronary intervention.
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Fig. 2 - Kaplan–Meier curves showing cumulative probability of (A) all-cause mortality; (B) target vessel revascularization; (c) stent throm-
bosis; (D) myocardial infarction after PCI according to stent group. BMS = bare metal stent; DES = drug-eluting stent; PCI = percutaneous 
cornary intervention. 
TABLe II - Procedural characteristics according to stent type
DES (n = 313) BMS (n = 344) Significance
Distal protection (%)f 98 (30.3) 115 (34.4) 0.08
GP IIb/IIIA use (%) 175 (54.2) 166 (49.7) 0.06
Number stents used 1.68 ± 0.7 1.66 ± 0.6 0.56
Stent length 29.05 ± 7.4 19.0 ± 5.9 0.19
Stent width 3.20 ± 0.4 3.70 ± 0.5    <0.0001
Angiographic success 303 (93.8%) 310 (92.8%) 0.78
p<0.05.
BMS = bare metal stent; DES = drug-eluting stent; GP = glycoprotein.
difference in the hazard of all-cause mortality (hazard ratio 
(HR) 1.08; 95% CI 0.77-1.68). The above Cox proportional haz-
ard model was repeated with the year of procedure included 
as a categorical variable to allow for improvements in PCI 
technique and technology over the long study period. This 
confirmed the association between DES use and improved 
MACE rates (HR 0.79; 95% CI 0.53-0.96) Table III illustrates the 
Cox proportional model of univariate and multivariate analy-
sis of predictors of major adverse cardiac events after PCI. 
Subgroup analysis
On subgroup analysis comparing different types of DES 
there was no significant difference in MACE rates between 
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old- and new-generation DES (198 stents were old-gen-
eration DES, and 179 were new-generation DES). Neither 
stent thrombosis (relative risk (RR) 1.19, 95% CI 0.70-1.80, 
p = 0.48), restenosis (RR 0.95, 95% CI 0.55-1.49, p = 0.54) 
nor death (RR 1.13, 95% CI 0.74-1.29, p = 0.44) were statis-
tically significantly improved with new-generation vs. old-
generation DES.
Influence of stent diameter (Fig. 4)
In the study cohort there were 206 patients who had stent 
diameters ≥4 mm with the remaining 426 patients having 
stent diameters <4 mm. The larger diameter (≥4 mm) cohort 
were split into 101 DES and 105 BMS. In this cohort there 
were no differences in MACE after 5 years with DES compared 
Fig. 3 - Hazard ratios after multivariate analysis for baseline and procedural characteristics. ACS = acute coronary syndrome; CI = confidence 
interval; CRF = chronic renal failure; DES = drug-eluting stent; EF = ejection fraction; GP = glycoprotein; MI = myocardial infarction.
TABLe III - Cox proportional model of univariate and multivariate analysis of predictors of major adverse cardiac events after PCI
Variable Comparator Univariate Multivariate*
Age 1.01 (1.00-1.03) 1.01 (1.00-1.02)
Female Male 0.84 (0.61-1.16) NA
ACS Non-ACS 1.63 (1.14-2.05) 1.35 (1.08-1.95)
Hypertension No hypertension 0.95 (0.71-1.28) NA
Hypercholesterolaemia No hypercholesterolaemia 0.94 (0.69-1.28) NA
Diabetic Non-diabetic 1.41 (1.03-1.93) 1.26 (1.06-2.01)
Previous MI No previous MI 1.24 (1.03-2.00) 1.37 (0.97-1.93)
EF<40 EF>40 2.28 (2.02-3.58) 1.70 (1.47-3.00)
CRF No CRF 2.81 (1.18-4.75) 2.28 (1.38-3.40)
Stent length 1.01 (0.99-1.02) NA
Stent width 0.99 (0.92-1.08) NA
GP IIb/IIIa No GP IIb/IIIa 0.95 (0.71-1.27) NA
Procedural success Failure 0.84 (0.74-0.95) 0.68 (0.60-0.79)
DES BMS 0.57 (0.43-0.75) 0.75 (0.52-0.94)
ACS = acute coronary syndrome; BMS = bare metal stent; CRF = chronic renal failure; DES = drug-eluting stent; DM = diabetes mellitus; EF = ejection fraction;  
GP = glycoprotein; MI = myocardial infarction; PCI = percutaneous coronary intervention.
* Adjusted for age, DM, previous MI, CRF, EF, ACS presentation and procedural success; * = significant association in multivariate analysis.
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with BMS (11.9%, 95% CI 8.1-14.2% vs. 15.2%, 95% CI: 9.4-
12.7%, p = 0.317) (Fig. 4A), with no difference in rates of TVR, 
death, MI or stroke between the stent types. Rates of defi-
nite/confirmed stent thrombosis were comparable for BMS 
and DES in this larger stent cohort (0.6%, 95% CI: 0.2-1.9% vs. 
0.9%, 95% CI 0.1-1.7%, p = 0.8).
In the smaller stent diameter cohort (<4 mm diameter) 
MACE after 5 years were significantly less frequent with DES 
compared with BMS (20.5%, 95% CI 10.8-13.8% vs. 38.2%, 
95% CI: 19.9-45.1%, p = 0.0007), driven by decreased TVR in 
the DES group (14.9%, 95% CI 9.0-16.5% vs. 28.8%, 95% CI 
15.0-32.3%, p = 0.0008). There was no difference in death, 
MI, stent thrombosis or stroke between the stent types in the 
smaller diameter cohort (Fig. 4B).
Discussion
This is a large observational study with one of the longest 
follow-up periods yet reported. Propensity matching is uti-
lized, which is only the case in few other studies (13-15). We 
specifically compared outcomes for patients with SVG disease 
treated by PCI with drug eluting as compared with BMS. DESs 
were associated with significantly lower 5-year MACE rates 
compared with BMSs in both elective and ACS subgroups. 
This difference was primarily driven by lower rates of repeat 
TVR by PCI. Rates of late stent thrombosis and subsequent 
AMI were low, with no difference between the BMS and DES 
groups. Therefore, the use of DES in the proximal SVG was 
not associated with an increase in late-stent thrombosis or 
long-term mortality compared with BMS. Due to the fact that 
this difference was driven by TVR we also looked into the ef-
fect of stent diameter on MACE. Interestingly there was no 
difference comparing BMS and DES for stents above 4 mm in 
diameter.
The degeneration of SVG appears to be a different phe-
nomenon compared with the progression of coronary artery 
atherosclerosis in native vessels (7, 8). In native vessels the 
cause of restenosis is almost exclusively due to neointima 
proliferation (9), while in SVGs exposed to the arterial circu-
lation variable degrees of contribution have been reported 
for thrombus formation, cellular hyperplasia and progres-
sion of atherosclerotic process (10). Acute thrombosis is the 
dominant aetiology in the early postoperative period. This 
is related to the size of the target vessel and distal run-off, 
size mismatch between the graft and the target vessel, graft 
ischemia and disruption of the endothelial layer as a result 
of mechanical trauma and manual distention. Initially intimal 
hyperplasia is seen, which is caused by the graft’s adapta-
tion to higher arterial pressures and loss of inhibition from 
the endothelial layer. Later on atherosclerosis becomes the 
major reason for graft stenosis and occlusion. As in native 
coronary arteries, vein graft atheromas can rupture and 
cause thrombotic occlusion of the graft (16). Vein graft ath-
eromas are also more diffuse and concentric. They are less 
calcified and have poorly developed or absent fibrous caps 
(17). Vein graft failure is also associated with worse clinical 
outcomes. A study on 1,243 patients, who previously under-
went CABG surgery and were followed up for a median of 
6.7 years, reports a significant increase in the composite end 
point of death, nonfatal MI or revascularization in patients 
who had critical or occlusive vein graft disease on angiogra-
phy compared with patients who had noncritical or no vein 
graft disease. This was primarily driven by TVR (18). Due to 
the difference in the pathophysiology of vein graft stenosis, 
investigating the long-term outcomes of these patients is 
essential.
Our finding of better outcomes for DES compared with 
BMS in a representative PCI population with SVG disease 
Fig. 4 - Kaplan–Meier curves showing cumulative probability of major adverse cardiac events for (A) stents ≥4 mm diameter and (B) stents 
<4 mm diameter according to stent group. BMS = bare metal stent; DES = drug-eluting stent.
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bears comparison with the selected populations included in 
recent clinical trials of DES vs. BMS. The ISAR-CABG trial, a 
randomized controlled superiority trial, reported decreased 
MACE rates for DES compared with BMS in subgroups un-
dergoing SVG stenting after 1 year follow-up (19). Again 
it was TVR that drove MACE in both groups, although the 
MACE rates for DES in our study were slightly higher (17.9% 
DES vs. 31.2% BMS group (p = 0.04) over the 5-year follow-
up than with the rate in ISAR-CABG (19) (15% for DES group 
and 22% for BMS group (p = 0.02)). A recent meta-analysis 
on 22 studies concluded that DES in vein graft PCI was as-
sociated with a decreased reintervention rates and all-cause 
mortality compared with BMS. There was no difference in 
the risk of stent thrombosis and MI. No difference in mor-
tality was found in this study as was the case in the other 
major studies. The reasons for this are not outrightly appar-
ent, but may be related to case selection and heterogeneity 
of the studies in the meta-analysis leading to bias. Interest-
ingly, no difference in mortality was reported in randomized 
controlled trials in the sensitivity analysis (20). A further 
study investigating newer generation DES reveals no signifi-
cant difference as compared to early-generation stents over 
a follow-up period of four years (21), data consistent with 
our study where no difference between older and newer 
generation DES was seen.
Some safety concerns persist regarding stent thrombosis 
with DES implantation (1, 22, 23). In contrast to restenosis, 
which is considered to have a relatively benign clinical course, 
stent thrombosis is consistently associated with acute MI and 
the mortality is high (24). We documented low and compa-
rable rates of stent thrombosis for BMS and DES similar to the 
rates reported in other patient cohorts (23, 25). Importantly, 
we found no difference in long-term mortality between the 
DES and BMS groups. Our data show that DES deployment in 
the SVG is safe and exposes the patient to no greater risk than 
is associated with BMS deployment.
Importantly, the significant difference between the BMS 
and DES is not evident for stent diameters above 4 mm. This 
has not been reported in the literature as yet. Operators can 
therefore consider implanting BMS with large diameter with-
out substantial safety concerns. This is especially important 
for patients with contraindications to long-term antiplatelet 
therapy.
Strengths and limitations of this study
As all patients were treated at a single centre with stan-
dardized care protocols and pathways, the effect of bias due 
to different treatment strategies is limited. Our cohort has 
large patient numbers. The long-term follow-up based on 
all-cause mortality and the investigation of both acute and 
elective cases add to the study strengths. The univariate, 
multivariate and propensity analysis highlights the quality 
of the data with well-recognized predictors of mortality as-
sociated with adverse outcome in our data set. Although 
this was not a randomized study the two patient groups ap-
pear well matched with respect to baseline and procedural 
characteristics.
There are a number of important limitations common 
to observational studies of this type. Importantly this study 
has all the limitations of a registry and all the potential bias 
and unmeasured confounding associated with non-random-
ized studies. In addition we cannot exclude the possibility of 
under-reporting of complications although the tracking of 
mortality is robust and we only included patients who had 
definitive mortality data in our study cohort. We cannot ac-
count for the effects of residual confounding or of selection 
bias caused by exclusion of 14% of patients with missing data 
or no NHS unique number. However, this is unlikely as the dis-
tribution of SVG disease and use of DES or BMS was the same 
in the excluded and analysed cohorts.
Conclusions
In this long-term observational study of PCI for SVG dis-
ease, DES was associated with a lower MACE rate than BMS 
due to a decreased need for repeat revascularization with no 
differences in rates of stent thrombosis, MI or all-cause mor-
tality between the groups. However, for stents with a diame-
ter above 4 mm no difference was seen between stent types. 
This suggests that although DES deployment in SVGs is both 
safe and clinically more effective than BMS for vessels ≥4 mm, 
BMSs are a viable alternative.
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